Significance Of The Alteration Of Th17 Cells In Patients With Guilla In-barre Syndrome

Background and purposeTraditionally, it has been shown that the CD4+T cells can be induced to secrete IFN-y (Thl) or secrete IL-4 and IL-10 (Th2) in a mutually exclusive manner. However, recently a new subset of activated CD4+T cell, reffered to as Thl7-cell subset, was identified. Previous studies have indicated that Th17-cell subset plays a vital role in the development of some autoimmune disease Such as CIA, EAE, cystic fibrosis or asthma.Th17-cell subset was distinct from the traditional Th1 and TH2-cell subset, and its generation from native precursors was not dependent on the cytokines transcription factors which mediate Thl and Th2-cell development. TGF-βplus IL-6 induced development of Thl7-cell from native T cells. The orphan nuclear receptor RORyt has been identified as the key transcription factors in the regulation of Th17 cell differentiation. IL-17, a prominent cytokine produced by Th17-cell play a important role in many autoimmune disease. In this study, we investigate the alteration and its significance of Th17 in patients with Guillain-barre syndrome (GBS).MethodsPeripheral blood mononuclear cells from normal and GBS were Separated, and followed by stimulation with phorbol myristate acetate (PMA) plus ionomycin (P/I). TH-17 cells in peripheral blood was determined by flow cytometry. The concentrations of Th17-related plasma cytokine IL-17 were measured by enzyme-linked immunosorbent assay.ResultsThe percentage of TH-17 cells (CD4+IL-17+) was higher (P<0.05) in GBS PB (1.56±0.51)% compared with normal PB (0.57±0.23)%. Th17 related cytokine IL-17 markedly increased in patients with GBS [15.94±3.75] ng/L compared with normal PB [8.19±0.98] ng/L. The concentration of clinical score was positively correlated with IL-17 (r=0.880, P<0.01) and Th17(r=0.899, P<0.01).ConclusionThe frequencies of Th17 in-creased in patients with acute coronary syndrome which may suggest a potential role for Thl7 in the athogenesis of GBS, suggesting that Th17 could be a potent target for treatment autoimmune neuropathies.